According to Svetlana Dey, President and CEO of Bluejay, "Our collaboration with Hitachi Chemical in developing a total tear IgE non-invasive test complements Bluejay's research and development strategy of tailored point-of-care diagnostics, or in other words, finding the right material and technology at the right time for patients. Through our collaboration with Hitachi Chemical, we hope to deliver non-invasive, rapid, point-of-care tests that enhance patient care and just as importantly avoid unnecessary treatment regimens, such as antibiotics."
The agreement will provide Bluejay with access to Hitachi Chemical's Allerwatch™ product - currently marketed in Japan for diagnosis of Allergic Conjunctivitis - for exclusive development, marketing and manufacturing in North America, South America and Europe.
About Hitachi Chemical Co., Ltd.
Hitachi Chemical Co., Ltd. (Tokyo Stock Exchange：4217), headquartered in Tokyo, Japan, delivers wide range of innovative products, such as electronic materials, automobile parts, energy storage devices and systems, in global markets. The company's consolidated revenues for fiscal 2015 (ended March 31, 2016) totaled 547 billion yen ($4.8 billion). For more information on Hitachi Chemical, please visit the company's website at http://www.hitachi-chem.co.jp/english/.
About Bluejay Diagnostics, Inc.
Bluejay Diagnostics, Inc., headquartered in Acton, Massachusetts, develops, manufactures and markets non-invasive, point-of-care (POC) tests that provide patients and providers access to affordable and timely healthcare in markets with unmet needs. The company's flagship product, a POC test for Allergic Conjunctivitis, is currently undergoing U.S. FDA 510(k) clinical trials with an expected launch in late 2017.
Contact: Jeffrey Aidt
Senior Director, Corporate Marketing
Tel: 978 631 4870
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bluejay-diagnostics-inc-announces-clinical-research-collaboration-to-develop-point-of-care-test-for-allergic-conjunctivitis-300412809.html
SOURCE Bluejay Diagnostics, Inc.